News
MacroGenics (MGNX) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
MacroGenics (NASDAQ: MGNX)Q4 2023 Earnings CallMar 07, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Why Viking Therapeutics Stock Is Plunging Today
Shares of Viking Therapeutics (NASDAQ: VKTX) were plunging 17.4% lower as of 11:52 a.m. ET on Thursday. This decline wasn't caused by an announcement by Viking. Instead, the sell-off appears to be
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
The day after Intellia Therapeutics (NASDAQ: NTLA) updated investors with its results for the fourth quarter on Feb. 23, Cannacord Genuity analyst Whitney Ijem issued a new price target for the
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?
Just when the weight-loss drug market was heating up, the temperature rose even more. Eli Lilly (NYSE: LLY) is already giving Novo Nordisk (NYSE: NVO) a run for its money with the approval in the
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
The weight loss drug market has been one of the most talked-about investing trends over the past year. One of the leaders in this area is Denmark-based Novo Nordisk (NYSE:NVO), thanks to its type 2
Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly
The gold rush for anti-obesity medicines is here, and the stakes are high. Per a report by Morgan Stanley Research, the market for weight loss drugs will be worth around $77 billion by 2030, despite
1 Wall Street Analyst Thinks Viking Therapeutics Stock Is Going to $116. Is It a Buy Around $81?
With shares of Viking Therapeutics (NASDAQ: VKTX) flying 555% higher in the last three months, at least one financial analyst is saying that it can go even higher. On Feb. 28, Oppenheimer's Jay
Is Novavax a Buy Now?
Novavax (NASDAQ: NVAX) has taken investors on a roller coaster ride over the past week or so. The stock soared after the company settled a dispute with a big customer, then sank as it reported
Better Buy: Eli Lilly vs. Viking Therapeutics
Comparing Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) might initially seem odd. The two drugmakers don't seem to have much in common. Eli Lilly is more than 50 times the size of
Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.
After rising by 137% in one day upon the publication of favorable phase 2 clinical trial results on Feb. 27, Viking Therapeutics (NASDAQ: VKTX) is now doubtlessly on many investors' radars. Soon
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
Technically, there is no upper limit to how much money investors can make from stocks in five years, but turning $1,000 into $2,500 is no easy task. That requires a compound annual growth rate
1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?
Since 2021, shares of Novavax (NASDAQ: NVAX) have absolutely crumbled, falling by a whopping 95%. Even with the price rally in recent days, the stock has still been a disastrous investment over the
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Karyopharm Therapeutics (NASDAQ: KPTI)Q4 2023 Earnings CallFeb 29, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Viking Therapeutics: A Teachable Moment About Investing for the Long Term
On Tuesday, Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech specializing in treatments for metabolic diseases, saw its stock price surge by a staggering 121% in response to a clinical
Viking Therapeutics Just Soared 120% on Optimism About Its Weight Loss Candidate. Too Late to Buy?
The weight loss drug market is growing in leaps and bounds -- and today the biggest winners are Eli Lilly and Novo Nordisk. These big pharma companies are bringing in billions thanks to their drugs
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
You've no doubt seen mutual fund warnings that past performance isn't necessarily indicative of future results. This caution applies to stocks as well. However, it doesn't just mean that investments
Is Viking Therapeutics a Buy Now?
Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech, more than doubled recently. The market started hurling money at the stock after some mid-stage clinical trial results
Geron (GERN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q4 2023 Earnings CallFeb 28, 2024, 8:00 a.m. ET
Operator
Source Fool.com
EQS-News: Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care
MannKind (MNKD) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
MannKind (NASDAQ: MNKD)Q4 2023 Earnings CallFeb 27, 2024, 5:00 p.m. ET
Operator
Source Fool.com
Why Novo Nordisk and Eli Lilly Stocks Slipped Today
The arrival of a potential new rival in an important product category dinged the share prices of pharmaceutical companies Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) on Tuesday. Both slumped
Has Novavax Just Solved Its Biggest Problem?
Many investors have seen Novavax (NASDAQ: NVAX) as a promising recovery story ever since the biotech launched a plan to cut costs to better match the revenue opportunities ahead of it. Once one of
Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Dynavax Technologies (NASDAQ: DVAX)Q4 2023 Earnings CallFeb 22, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Axsome Therapeutics (NASDAQ: AXSM)Q4 2023 Earnings CallFeb 20, 2024, 8:00 a.m. ET
Operator
Source Fool.com